哮喘是新冠病毒病的一个风险因素吗？表型重要吗？
Is asthma a risk factor for COVID-19? Are phenotypes important?
作者信息
Muñoz Xavier, Pilia Florencia, Ojanguren Iñigo, Romero-Mesones Christian, Cruz María-Jesús
机构信息
Servei de Pneumologia Hospital Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
出版信息
ERJ Open Res. 2021 Jan 25;7(1). doi: 10.1183/23120541.00216-2020. eCollection 2021 Jan.
Abstract
摘要
https://bit.ly/38hIp18. （此为链接，无法准确翻译其内容，保留原文形式）
相似文献
1
Is asthma a risk factor for COVID-19? Are phenotypes important?哮喘是新冠病毒病的一个风险因素吗？表型重要吗？
ERJ Open Res. 2021 Jan 25;7(1). doi: 10.1183/23120541.00216-2020. eCollection 2021 Jan.
2
Inhaled corticosteroids and COVID-19 outcomes in asthma: the Israeli experience.吸入性糖皮质激素与哮喘患者的 COVID-19 结局：以色列的经验
ERJ Open Res. 2022 Mar 7;8(1). doi: 10.1183/23120541.00014-2022. eCollection 2022 Jan.
3
The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?英国首次新冠疫情高峰对重度哮喘患者的影响。哪个更糟糕：病毒还是封锁措施？
ERJ Open Res. 2021 Feb 1;7(1). doi: 10.1183/23120541.00768-2020. eCollection 2021 Jan.
4
The polyhedric reality of the interaction between COVID-19, asthma and inhaled corticosteroids.新型冠状病毒肺炎、哮喘与吸入性糖皮质激素之间相互作用的多面现实
ERJ Open Res. 2022 May 30;8(2). doi: 10.1183/23120541.00179-2022. eCollection 2022 Apr.
5
Impact of COVID-19 on COPD and asthma admissions, and the pandemic from a patient's perspective.从患者角度看2019冠状病毒病对慢性阻塞性肺疾病和哮喘住院情况的影响以及疫情
ERJ Open Res. 2021 Feb 8;7(1). doi: 10.1183/23120541.00822-2020. eCollection 2021 Jan.
6
Poor quality research and clinical practice during COVID-19.新冠疫情期间质量欠佳的研究与临床实践。
Breathe (Sheff). 2020 Jun;16(2):200112. doi: 10.1183/20734735.0112-2020.
7
Radiological-pathological signatures of patients with COVID-19-related pneumomediastinum: is there a role for the Sonic hedgehog and Wnt5a pathways?新型冠状病毒肺炎相关纵隔气肿患者的放射学-病理学特征：音猬因子和Wnt5a信号通路是否起作用？
ERJ Open Res. 2021 Aug 23;7(3). doi: 10.1183/23120541.00346-2021. eCollection 2021 Jul.
8
COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth.两名接受贝那利珠单抗治疗的重度哮喘患者感染新型冠状病毒肺炎：打破嗜酸性粒细胞增多的误区
ERJ Open Res. 2020 Nov 2;6(4). doi: 10.1183/23120541.00457-2020. eCollection 2020 Oct.
9
Microparticles in COVID-19 as a link between lung injury extension and thrombosis.新冠病毒肺炎中的微粒作为肺损伤扩展与血栓形成之间的联系。
ERJ Open Res. 2021 Jun 21;7(2). doi: 10.1183/23120541.00954-2020. eCollection 2021 Apr.
10
Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space.关于重组组织型纤溶酶原激活剂在新型冠状病毒肺炎中应用的观察性研究表明生理死腔减少。
ERJ Open Res. 2020 Oct 5;6(4). doi: 10.1183/23120541.00455-2020. eCollection 2020 Oct.
引用本文的文献
1
SARS-CoV-2 in Asthmatic Children: Same Consequences in Different Endotypes?哮喘儿童感染严重急性呼吸综合征冠状病毒2：不同内型会有相同后果吗？
Metabolites. 2025 Jun 16;15(6):406. doi: 10.3390/metabo15060406.
2
Respiratory sequelae in patients with bronchial asthma after SARS-CoV-2 pneumonia: a retrospective study in a large academic centre in 2020.新型冠状病毒肺炎后支气管哮喘患者的呼吸后遗症：2020年在一个大型学术中心进行的回顾性研究
ERJ Open Res. 2025 Feb 10;11(1). doi: 10.1183/23120541.00510-2024. eCollection 2025 Jan.
3
Significant association between asthma and a lower risk of mortality among COVID-19 patients in Spain: A meta-analysis.西班牙COVID-19患者中哮喘与较低死亡风险之间的显著关联：一项荟萃分析。
Qatar Med J. 2024 Jul 4;2024(3):34. doi: 10.5339/qmj.2024.34. eCollection 2024.
4
Spatial Survival Model for COVID-19 in México.墨西哥新冠肺炎的空间生存模型
Healthcare (Basel). 2024 Jan 24;12(3):306. doi: 10.3390/healthcare12030306.
5
Long COVID outcomes in an asthmatic cohort and its implications for asthma control.哮喘队列中的长期新冠病毒感染结局及其对哮喘控制的影响。
Respir Med. 2023 Feb;207:107092. doi: 10.1016/j.rmed.2022.107092. Epub 2022 Dec 16.
6
Determinants of COVID-19 Breakthrough Infections and Severity in ChAdOx1 nCoV-19-Vaccinated Priority Groups.接种 ChAdOx1 nCoV-19 疫苗的优先群体中 COVID-19 突破性感染和严重程度的决定因素。
Am J Trop Med Hyg. 2022 Aug 8;107(4):850-855. doi: 10.4269/ajtmh.22-0172. Print 2022 Oct 12.
7
Persistent Health Issues, Adverse Events, and Effectiveness of Vaccines during the Second Wave of COVID-19: A Cohort Study from a Tertiary Hospital in North India.第二波新冠疫情期间的持续健康问题、不良事件及疫苗有效性：来自印度北部一家三级医院的队列研究
Vaccines (Basel). 2022 Jul 20;10(7):1153. doi: 10.3390/vaccines10071153.
8
The polyhedric reality of the interaction between COVID-19, asthma and inhaled corticosteroids.新型冠状病毒肺炎、哮喘与吸入性糖皮质激素之间相互作用的多面现实
ERJ Open Res. 2022 May 30;8(2). doi: 10.1183/23120541.00179-2022. eCollection 2022 Apr.
9
An update on the epidemiology of pediatric COVID-19 in Brazil.巴西儿童新冠病毒肺炎流行病学最新情况
Rev Paul Pediatr. 2022 Apr 4;40:e2021367. doi: 10.1590/1984-0462/2022/40/2021367. eCollection 2022.
10
COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome.新型冠状病毒肺炎、重度哮喘与奥马珠单抗治疗：基于病例对关联、管理及改善预后可能性的探究
Turk Thorac J. 2021 Nov;22(6):501-506. doi: 10.5152/TurkThoracJ.2021.20329.
本文引用的文献
1
Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.2 型炎症调节气道上皮细胞中的 ACE2 和 TMPRSS2。
J Allergy Clin Immunol. 2020 Jul;146(1):80-88.e8. doi: 10.1016/j.jaci.2020.05.004. Epub 2020 May 15.
2
Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2.呼吸道过敏、哮喘与新型冠状病毒受体血管紧张素转换酶2表达的关联。
J Allergy Clin Immunol. 2020 Jul;146(1):203-206.e3. doi: 10.1016/j.jaci.2020.04.009. Epub 2020 Apr 22.
3
Clinical Characteristics of Covid-19 in New York City.纽约市新冠肺炎的临床特征
N Engl J Med. 2020 Jun 11;382(24):2372-2374. doi: 10.1056/NEJMc2010419. Epub 2020 Apr 17.
4
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.武汉成人 COVID-19 住院患者严重程度和死亡率的危险因素。
J Allergy Clin Immunol. 2020 Jul;146(1):110-118. doi: 10.1016/j.jaci.2020.04.006. Epub 2020 Apr 12.
5
Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?慢性呼吸道疾病或其治疗是否会影响感染SARS-CoV-2的风险？
Lancet Respir Med. 2020 May;8(5):436-438. doi: 10.1016/S2213-2600(20)30167-3. Epub 2020 Apr 3.
6
Covid-19 in Critically Ill Patients in the Seattle Region - Case Series.西雅图地区危重症新冠患者-病例系列。
N Engl J Med. 2020 May 21;382(21):2012-2022. doi: 10.1056/NEJMoa2004500. Epub 2020 Mar 30.
7
Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020.2020 年 1 月 19 日至 3 月 2 日韩国 2019 年冠状病毒病（COVID-19）疫情的流行病学特征报告。
J Korean Med Sci. 2020 Mar 16;35(10):e112. doi: 10.3346/jkms.2020.35.e112.
8
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
9
Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.格隆溴铵、福莫特罗和布地奈德对人鼻和气管上皮细胞原代培养物中冠状病毒HCoV-229E复制及细胞因子产生的抑制作用。
Respir Investig. 2020 May;58(3):155-168. doi: 10.1016/j.resinv.2019.12.005. Epub 2020 Feb 21.
10
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.中国武汉 140 名 SARS-CoV-2 感染患者的临床特征。
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
Zotero 插件